Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Gaucher Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.42

    Glucosylceramide Synthase Inhibitors for Gaucher Disease and Niemann-Pick Disease (Elelyso, Cerdelga, Cerezyme, VPRIV, and miglustat/Yargesa/Zavesca)

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.42 alerts

    Get alerted when Policy 05.02.42 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage, prior authorization, preferred-product requirements, medical-necessity criteria, continuation criteria, and dosing or quantity limits for therapies used to treat type 1 or type 3 Gaucher disease and Niemann-Pick disease type C.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyGlucosylceramide Synthase Inhibitors for Gaucher Disease and Niemann-Pick Disease
    Policy CodePolicy 05.02.42
    Change TypeNo material change
    Effective DateJune 6, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical and diagnostic information when requesting prior authorization.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred Gaucher disease products
    7Covered brands or generics
    4Disease categories addressed
    12 monthsApproval duration
    15-60Weight-based vial limits
    3Listed billing codes

    Coverage Criteria

    Initial approval for enzyme replacement therapies

    Covered when all applicable criteria are met.

    Elelyso for Gaucher disease type 1

    • ALL of the following

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • ONE of

        • Member is currently receiving Elelyso, excluding treatment obtained as samples or through a manufacturer's patient assistance program.
        • Member has a documented inadequate response or intolerable adverse event with preferred Cerezyme.

    Elelyso for Gaucher disease type 3

    • ALL of the following

      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • ONE of

        • Member is currently receiving Elelyso, excluding treatment obtained as samples or through a manufacturer's patient assistance program.
        • Member has a documented inadequate response or intolerable adverse event with preferred Cerezyme.

    VPRIV for Gaucher disease type 1 or type 3

    • ONE of

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    Cerezyme for Gaucher disease type 1 or type 3

    • ONE of

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    Initial approval for oral therapies

    Covered when all applicable criteria are met.

    Cerdelga for Gaucher disease type 1

    • Member is at least 18 years of age.
    • Diagnosis of Gaucher disease is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
    • Member is a CYP2D6 extensive, intermediate, or poor metabolizer as detected by an FDA-cleared test.

      CYP2D6 ultra-rapid and indeterminate metabolizers are not eligible because an adequate therapeutic dose cannot be recommended.

    Miglustat, Yargesa, or Zavesca for Gaucher disease type 1

    • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    Continuation therapy

    Covered for continuation when all applicable criteria are met.

    Cerezyme, Elelyso, or VPRIV continuation

    • Member is receiving treatment for Gaucher disease type 1 or type 3.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

    Cerdelga continuation

    • Member meets the criteria for initial approval for Cerdelga treatment of Gaucher disease type 1.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

    Miglustat, Yargesa, or Zavesca continuation for Gaucher disease type 1

    For Cerdelga, patients who are CYP2D6 ultra-rapid metabolizers may not achieve adequate drug concentrations for a therapeutic effect. A specific Cerdelga dosage cannot be recommended when the patient’s CYP2D6 genotype cannot be determined, referred to as an indeterminate metabolizer.

    Elelyso, VPRIV, Cerezyme, Cerdelga, miglustat, Yargesa, and Zavesca are considered not medically necessary when the patient does not meet the applicable approval criteria. Patients receiving the requested medication through samples or a manufacturer’s patient assistance program must still meet the initial-approval criteria.

    Billing and Coding

    Listed HCPCS CodesHCPCS
    J3060Inj, taliglucerace alfa 10 units (Elelyso)
    J1786Inj, imiglucerase, 10 units (Cerezyme)
    J3385Inj, velaglucerase alfa, 100 units (VPRIV)
    Patient weight dosing tier
    Patient weight under 100 kg (220.5 lbs)Use the under-100-kg dosing tier.
    Patient weight over 100 kg (220.5 lbs)Use the over-100-kg dosing tier.
    Dosing-limit intervalLimits are applied per 14 days.

    Provider Requirements and Decision Risks

    Prior Authorization

    Prior Authorization Required

    Submit the required clinical and diagnostic information to initiate prior authorization review for the requested therapy.

    • Include diagnosis-specific testing, CYP2D6 results when applicable, treatment history, and other information needed to evaluate medical necessity.
    Step Therapy

    Preferred Enzyme Replacement Therapy

    Cerezyme and VPRIV are the preferred enzyme replacement products. Coverage for Elelyso requires documentation of a clinical circumstance excluding use of the preferred product, which may include prior use and an inadequate response or intolerable adverse event with Cerezyme.

    • Cerdelga and Zavesca/Yargesa/miglustat are excluded from the preferred-product requirement.
    • Elelyso is covered only when the applicable Gaucher disease criteria and preferred-product exception are documented.

    Policy Background

    This policy addresses therapies for lysosomal storage disorders, including Gaucher disease types 1 and 3 and Niemann-Pick disease type C. Treatment options include enzyme replacement therapies and oral substrate-reduction therapies. Coverage and authorization depend on confirmation of the applicable diagnosis through enzyme activity testing or disease-specific genetic testing; Cerdelga selection additionally requires assessment of CYP2D6 metabolizer status.

    Metabolizer Status Definitions

    CYP2D6 ultra-rapid metabolizer (URM)
    URM statusA CYP2D6 ultra-rapid metabolizer has a genotype associated with substantially increased metabolism.
    Cerdelga concentrationPatients with URM status may not achieve adequate Cerdelga concentrations to achieve a therapeutic effect.
    Coverage implicationCerdelga is not eligible under the stated limitation for CYP2D6 ultra-rapid metabolizers.
    CYP2D6 EM, IM, or PM
    Eligible statusesCYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM).
    Testing basisStatus must be detected by an FDA-cleared test.

    Initial Therapy

    Initial therapy

    Initial therapy is covered only when the drug-specific diagnosis, treatment-history, age, testing, and metabolizer criteria are met.

    Elelyso initial therapy

    • Gaucher disease type 1 or type 3 diagnosis

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
    • ONE of

      • Member is currently receiving Elelyso, excluding treatment obtained as samples or through a manufacturer's patient assistance program.

    Continuation Therapy

    Continuation criteria

    Continuation is covered when the member meets the applicable criteria and is not experiencing inadequate response or intolerable adverse events.

    Enzyme replacement continuation

    • Cerezyme, Elelyso, or VPRIV is being continued for Gaucher disease type 1 or type 3.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

    Cerdelga continuation

    • Member meets the criteria for initial approval for Cerdelga treatment of Gaucher disease type 1.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

    Preferred Product and Step Requirements

    StepPreferred or requested therapyCoverage requirement
    1Cerezyme or VPRIVPreferred enzyme replacement products for Gaucher disease type 1 or type 3 when diagnosis is confirmed by beta-glucocerebrosidase enzyme assay or genetic testing.
    StepTherapyCoverage requirement

    Quantity and Dosing Limits

    Cerezyme
    Patient weight under 100 kg (220.5 lbs)15 400-unit vials per 14 days.
    Patient weight over 100 kg (220.5 lbs)30 400-unit vials per 14 days.
    Limit typeDosing limit for Cerezyme courses.
    Elelyso
    Patient weight under 100 kg (220.5 lbs)30 200-unit vials per 14 days.
    Patient weight over 100 kg (220.5 lbs)60 200-unit vials per 14 days.
    Limit typeDosing limit for Elelyso courses.
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyGlucosylceramide Synthase Inhibitors for Gaucher Disease and Niemann-Pick Disease
    Policy CodePolicy 05.02.42
    Change TypeNo material change
    Effective DateJune 6, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical and diagnostic information when requesting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Requirements and Decision RisksPolicy BackgroundMetabolizer Status DefinitionsInitial TherapyContinuation TherapyPreferred Product and Step RequirementsQuantity and Dosing Limits
  1. Member has a documented inadequate response or intolerable adverse events with enzyme replacement therapy.
  2. Miglustat, Yargesa, or Zavesca for Niemann-Pick disease type C

    • Diagnosis of Niemann-Pick disease type C is confirmed by genetic testing showing mutations in the NPC1 or NPC2 genes.NPC1 or NPC2 mutation
    Member is receiving treatment for Gaucher disease type 1.
  3. Member is not experiencing an inadequate response or any intolerable adverse events from therapy.
  4. Miglustat, Yargesa, or Zavesca continuation for Niemann-Pick disease type C

    • Member meets the criteria for initial approval.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.
    Step Therapy

    Enzyme Replacement Therapy Prerequisite

    Before requesting an oral Gaucher therapy, document the required treatment history with enzyme replacement therapy.

    • For Zavesca/Yargesa/miglustat for Gaucher disease type 1, document an inadequate response or intolerable adverse events with enzyme replacement therapy.
    Documentation Required

    Gaucher Disease Diagnostic Documentation

    Document Gaucher disease with a beta-glucocerebrosidase enzyme assay demonstrating deficient activity or with genetic testing. For Cerdelga, also submit the CYP2D6 test result.

    • The diagnostic documentation applies to the relevant Gaucher disease type and requested product.
    • CYP2D6 testing is required for Cerdelga.
    Documentation Required

    Niemann-Pick Disease Diagnostic Documentation

    For Niemann-Pick disease type C, submit genetic testing results showing mutations in the NPC1 or NPC2 genes.

    Documentation Required

    Cerdelga Prescriber Specialty Documentation

    Cerdelga must be prescribed by, or in consultation with, a physician who specializes in metabolic disease and/or lysosomal storage disorders.

    • Document the specialist prescriber or consultation in the authorization submission.
    Documentation Required

    Product-Specific Treatment History

    Submit product-specific treatment history supporting the requested therapy, including current use, clinical response, and adverse-event history.

    • For Elelyso, document current treatment, excluding use obtained as samples or through a manufacturer patient assistance program, or document inadequate response or intolerance to preferred Cerezyme.
    • For Zavesca/Yargesa/miglustat for Gaucher disease, document inadequate response or intolerable adverse events with enzyme replacement therapy.
    • For continuation, document that the member is not experiencing an inadequate response or intolerable adverse events; applicable products include Cerezyme, Elelyso, VPRIV, Cerdelga, and Zavesca/Yargesa/miglustat.
    Denial Risk

    Failure to Meet Medical-Necessity Criteria

    The requested medication is not medically necessary and will not be covered when the applicable initial-approval criteria are not met.

    • Members receiving medication only through samples or a manufacturer patient assistance program must meet the initial-approval criteria.
    • Coverage is subject to the diagnosis, age, testing, treatment-history, and other product-specific requirements.
    Denial Risk

    Preferred-Product Requirement

    A non-preferred product may be denied when the submission does not document the required preferred-product exception. Cerezyme and VPRIV remain the preferred enzyme replacement products.

    • For Elelyso, document a clinical circumstance excluding preferred therapy, such as inadequate response or intolerance to Cerezyme, when applicable.
    • The preferred-product requirement does not apply to Cerdelga or Zavesca/Yargesa/miglustat.
    Denial Risk

    Cerdelga Metabolizer Status

    Cerdelga may not provide adequate therapeutic concentrations for CYP2D6 ultra-rapid metabolizers, and no specific dose can be recommended when the genotype is indeterminate.

    • Cerdelga requires an FDA-cleared CYP2D6 test showing extensive, intermediate, or poor metabolizer status.
    • Ultra-rapid or indeterminate metabolizer results create an ineligible status for Cerdelga coverage.
    Denial Risk

    Failure of Continuation Criteria

    Continuation coverage may be denied when the member does not meet the applicable continuation criteria or is experiencing an inadequate response or intolerable adverse events.

    • Cerdelga continuation requires that the initial-approval criteria continue to be met.
    • For Niemann-Pick disease type C, continuation of Zavesca/Yargesa/miglustat requires meeting initial-approval criteria and having no inadequate response or intolerable adverse events.
    • Continuation approval is for 12 months where specified.
    Cerdelga use
    These metabolizer statuses are eligible for Cerdelga when the other approval criteria are met.
    Indeterminate metabolizer
    Indeterminate statusThe CYP2D6 metabolizer status cannot be determined.
    Cerdelga dosingA specific Cerdelga dosage cannot be recommended.
    Coverage implicationCerdelga is not eligible under the stated limitation when the CYP2D6 genotype is indeterminate.
  5. Member has a documented inadequate response or intolerable adverse event with preferred Cerezyme.
  6. VPRIV initial therapy

    • Gaucher disease type 1 or type 3 diagnosis

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    Cerezyme initial therapy

    • Gaucher disease type 1 or type 3 diagnosis

      • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
      • Diagnosis of Gaucher disease type 3 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.

    Cerdelga initial therapy

    • Member is at least 18 years of age.>= 18 years
    • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
    • Member is a CYP2D6 extensive, intermediate, or poor metabolizer as detected by an FDA-cleared test.

      CYP2D6 ultra-rapid and indeterminate metabolizers are not eligible because an adequate therapeutic dose cannot be recommended.

    Miglustat, Yargesa, or Zavesca for Gaucher disease type 1

    • Diagnosis of Gaucher disease type 1 is confirmed by an enzyme assay demonstrating deficient beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
    • Member has a documented inadequate response or intolerable adverse events with enzyme replacement therapy.

    Miglustat, Yargesa, or Zavesca for Niemann-Pick disease type C

    • Diagnosis of Niemann-Pick disease type C is confirmed by genetic testing showing mutations in the NPC1 or NPC2 genes.NPC1 or NPC2 mutation

    Miglustat, Yargesa, or Zavesca continuation for Gaucher disease type 1

    • Member is receiving treatment for Gaucher disease type 1.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

    Miglustat, Yargesa, or Zavesca continuation for Niemann-Pick disease type C

    • Member meets the criteria for initial approval.
    • Member is not experiencing an inadequate response or any intolerable adverse events from therapy.
    VPRIV
    Patient weight under 100 kg (220.5 lbs)15 400-unit vials per 14 days.
    Patient weight over 100 kg (220.5 lbs)30 400-unit vials per 14 days.
    Limit typeDosing limit for VPRIV courses.
    Miglustat, Yargesa, or Zavesca
    Gaucher disease90 capsules per 30 days.
    Niemann-Pick disease, type C180 capsules per 30 days.
    ProductsMiglustat 100 mg capsule, Yargesa 100 mg capsule, or Zavesca 100 mg capsule.
    FDA-recommended daily dosing
    Gaucher diseaseFDA-recommended dosing is 300 mg per day, equivalent to one 100 mg capsule three times daily.
    Niemann-Pick disease, type CFDA-recommended dosing is 600 mg per day, equivalent to two 100 mg capsules three times daily.
    ProductsMiglustat 100 mg capsule, Yargesa 100 mg capsule, or Zavesca 100 mg capsule.
    Cerezyme
    Patients weighing <100 kgFifteen (15) 400-unit vials per 14 days.
    Patients weighing >100 kgThirty (30) 400-unit vials per 14 days.
    Policy wordingCerezyme dosing limits are stated as vials per 14 days.
    Elelyso
    Patients weighing <100 kgThirty (30) 200-unit vials per 14 days.
    Patients weighing >100 kgSixty (60) 200-unit vials per 14 days.
    Policy wordingElelyso dosing limits are stated as vials per 14 days.
    VPRIV
    Patients weighing <100 kgFifteen (15) 400-unit vials per 14 days.
    Patients weighing >100 kgThirty (30) 400-unit vials per 14 days.
    Policy wordingVPRIV dosing limits are stated as vials per 14 days.
    Miglustat, Yargesa, or Zavesca
    Gaucher disease90 capsules per 30 days.
    Niemann-Pick disease, type C180 capsules per 30 days.
    ProductsMiglustat 100 mg capsule (generic), Yargesa 100 mg capsule, and Zavesca 100 mg capsule.
    Miglustat, Yargesa, or Zavesca
    Gaucher disease300 mg per day, equivalent to one 100 mg capsule three times daily.
    Niemann-Pick disease, type C600 mg per day, equivalent to two 100 mg capsules three times daily.
    ProductsMiglustat 100 mg capsule (generic), Yargesa 100 mg capsule, and Zavesca 100 mg capsule.